



### About the placebo.

In order to understand if the study vaccine is effective in preventing the COVID-19 illness or SARS-CoV-2 infection, researchers are comparing the study vaccine to a placebo. A placebo generally looks just like the study drug or study vaccine being tested but contains no active medication or vaccine.

Participants will receive the same level of care from the study team regardless of if they are assigned to the study vaccine or the placebo. Participants will also be closely monitored by the study team if they do have symptoms of COVID-19 at any time throughout their participation.

If a participant is diagnosed with COVID-19 during their participation, the study team will provide them with frequent monitoring because the health and safety of all study participants are our top priorities.

### About the Cove Study.

The total length of participation is up to 25 months and includes approximately seven visits to the study site and 24 phone calls.



Participants will have two injection visits, which will happen on the first day and one month later. Participants will get their assigned injections of the study vaccine or placebo. Each participant has a 50% chance of receiving the study vaccine and a 50% chance of receiving the placebo.



Participants will be asked to return to the study site four more times within the next six months.



Participants will be contacted by the study team three times after each injection and then monthly after that to monitor for COVID-19 symptoms. During these phone calls, the study team will check how each participant is feeling and ask for updates on their health.



Participants will also be asked to complete weekly electronic diary entries reporting any COVID-19 symptoms for the duration of the study.




Participants will have one final visit to the study site approximately two years from the date of their second injection.

### COVID-19 diagnosis.

If a participant is diagnosed with COVID-19 during study participation, they will have two illness visits, which will occur at the study site. They will also need to attend daily telemedicine visits by videoconference or over the phone for 14 days after the diagnosis visit or until their symptoms have resolved, whichever is later. If a participant is unable to attend a site visit as a result of their health or the coronavirus pandemic, the study team may perform a home visit.

### Withdrawing from the Cove Study.

Participants have the right to withdraw from the study at any time for any reason. The study doctor or sponsor also has the right to discontinue a participant at any time in the interest of the participant's safety, or if the participant does not continue to meet eligibility requirements.



**Thank you for your interest  
in the Cove Study. Your participation  
could make a world of difference.**

**To learn more, contact the  
participating site listed here.**

**moderna**

mRNA-1273-P301\_Study Fact Sheet\_V1\_15July2020